Related Experiment Video
Updated: Mar 15, 2026
07:14
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
Published on: June 16, 2023
3.5K
Surface plasmon resonance-based immunoassay for procalcitonin.
Sandeep Kumar Vashist1, E Marion Schneider2, Eberhard Barth3
1Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, D-81675, Munich, Germany.
Analytica Chimica Acta
|September 14, 2016
Summary
A new surface plasmon resonance (SPR) biosensor enables rapid immunoassay of procalcitonin (PCT). This highly sensitive and reproducible method offers a faster immobilization strategy for improved detection.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Biosensing Technology
Background:
- Procalcitonin (PCT) is a crucial biomarker for bacterial infections.
- Accurate and rapid detection of PCT is essential for timely clinical decisions.
- Existing immunoassay methods can be time-consuming and lack optimal sensitivity.
Purpose of the Study:
- To develop a novel Surface Plasmon Resonance (SPR) biosensor for rapid and sensitive procalcitonin (PCT) immunoassay.
- To establish an efficient and reproducible antibody immobilization strategy on the SPR chip.
- To evaluate the performance of the developed biosensor for PCT detection in various sample matrices.
Main Methods:
- Utilized a single-step immobilization of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)-activated protein A (PrA) on a gold-coated SPR chip.
- Employed an oriented binding strategy for anti-PCT antibody (Ab) on the PrA-functionalized chip.
- Validated the biosensor's performance using standard PCT solutions, real sample matrices, and patient samples.
Main Results:
- Achieved a leach-proof and significantly faster (5x) PrA immobilization compared to conventional methods.
- Demonstrated high detection sensitivity for PCT, with a Limit of Detection (LOD) of 4.2 ng/mL and Limit of Quantification (LOQ) of 9.2 ng/mL.
- Confirmed high precision and reproducibility in detecting PCT in real sample matrices and patient samples, with sensor stability exceeding five weeks.
Conclusions:
- The developed SPR biosensor provides a rapid, sensitive, and reproducible platform for PCT immunoassay.
- The novel single-step immobilization strategy enhances assay efficiency and antibody orientation.
- This biosensor holds significant potential for clinical diagnostics and monitoring of PCT levels.
